Cohere launches AI health care agents in the U.S.
Cohere, founded in 2019, uses large-language models to build chatbots and generative-AI platforms for enterprise customers to automate some tasks.
The partnership with Ensemble, launched Tuesday, uses a customized version of the North by Cohere platform that will run on health care providers' internal systems and help with tasks such as hospitals appealing insurance-claim denials and chasing down accounts receivable.
The company said pre-launch tests of the tools accelerated denial appeals by 40 per cent and improved denial overturn rates by 15 per cent.
Running on internal systems is a key part of how the AI system protects the safety of patients' information and complies with privacy law, said Cohere co-founder Ivan Zhang.
'There's no data leaving their system, because all the agents are in the house,' he said.
Because of those privacy concerns, Mr. Zhang said the AI has to be trained on synthetic data, which would be similar to real-world data in likeness and structure but without any protected personal information.
The foray into health-care follows Cohere's work in the financial sector, which has to adhere to similar privacy rules. In January, the company announced a partnership with Royal Bank of Canada to co-develop and run a customized platform called North for Banking which, among other things, helps employees answer questions from customers.
Mr. Zhang said Cohere is focused on the U.S. market for now, but hopes to have more to announce for Canadian health-care soon.
'So far, we are focused on the U.S. markets. We want to take these learnings and adapt it to different systems in Canada and globally,' he said.
Cohere did not disclose any financial terms or which U.S. clients are using the AI platform.
The company also received a nod Tuesday from new federal AI minister Evan Solomon.
In a speech in Ottawa, Mr. Solomon outlined the government's new approach to AI, saying it would shift from 'warnings and regulation' to celebrating industry 'champions' such as Cohere.
Mr. Zhang said he was 'delighted' by the support and said there was a strong case to be made that investments in AI were part of strengthening Canada's economy and security.
'We've been very happy about the government's engagement so far,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 minutes ago
- Globe and Mail
Canada is hosting the world's biggest dementia conference for the first time in a decade. What's changed since then?
This week, researchers from around the globe are descending upon downtown Toronto to attend the Alzheimer's Association International Conference, the world's biggest and most influential meeting for dementia research. The gathering is a chance for the international dementia community to discuss the latest research in the field; it's also where significant breakthroughs are often unveiled. At a related event on Saturday, the Canadian Institutes of Health Research (CIHR) – Canada's health research funding agency – announced $44.8-million in new funding for dementia and aging-related research initiatives, including the creation of 16 teams that will study everything from Alzheimer's biomarkers to dementia in Indigenous populations. To set the stage for this year's conference, The Globe and Mail checked in with Jane Rylett, a professor at Western University and scientific director at the CIHR Institute of Aging, which hosted Saturday's event. The last time this global conference was held in Canada was in 2016, nearly a decade ago. How has the dementia research landscape changed since then? This is a really important inflection point. There is a new class of drugs, the antibody therapy, that came into the market within the last three or four years; they probably will be approved in Canada in the coming years. But while there's huge hope around it . . . right now, there's a lot of debate around if they're really beneficial. For certain people, they don't work at all; other people have negative side effects by creating inflammation in the brain. And the benefit-to-risk ratio is not great. So I think at this year's conference, it's going to be really important to hear about new findings with that. Something that's really gained momentum over the last few years is stepping back from the pharmacological approach to treatment and saying, 'What else can we do that will reduce the risk of developing dementia?' Health system urged to brace for major shift in dementia demographics The other thing that's changed is there's always been an 'amyloid hypothesis' of Alzheimer's disease, based on these toxic peptides that get made in the brain and clearly have a role in brain health and development of dementia. But during these nine years, there's been a much greater move towards understanding the role of those and recognizing that while they're still important, they're not the whole story. Now there's more openness to looking at other hypotheses about how brain health can be impacted during the life course and can lead to dementia. How should people feel about this present moment? Thinking back to 2012, the United States' health department set an ambitious goal to prevent and effectively treat Alzheimer's disease by 2025. But here we are today and that goal is far from met. When people or groups make those kinds of statements, it doesn't necessarily mesh with the complication of the thing. And then what happens is people see [the missed deadline] and think, well, it didn't happen. That's always the danger of doing something like that. The brain is a complex thing, it really is. The problem with something like Alzheimer's disease is it's so multi-faceted and it's a spectrum. There's so many areas of the brain that are impacted and the clinical presentation can look similar for people but what's happening in their brain, and where the degeneration is initiated, can be quite different. There's no one pill that you're going to have that's going to be able to change the course or alleviate the symptoms. So was it realistic to say in 2012 that this could be cured by 2025? Probably not. But it stimulated a lot of activity. We understand much more about the underlying pathology and the pathogenesis of the disease. And stepping back was an important thing, saying what can we do that is not a pharmaceutical or a pill? What are the life, behavioural and other things that we can do? Canada has a chance to change the Alzheimer's experience - let's not squander it There's been a lot of focus on the funding cuts in the U.S. that are under way right now, including to the National Institutes of Health (NIH). How has that affected things? is it looming over the conference this year? Yes. A number of Canadian researchers also have been funded by NIH, either in their own right or as subcontracts on larger studies within the U.S., and for the most part, that has been ended, which is very problematic. So we have a number of very good Canadian researchers in all fields that have lost substantial funding, and we don't have the resources in Canada to replace that. One of the big question marks is the impact it's going to have on the number of Americans that are going to be able to attend the conference. And I don't know the answer to that yet. Let's talk about Canadian researchers. What role are they playing within the broader effort? Canadian researchers are leaders internationally in these fields of study. There's really significant work being done by Canadians in the biomarkers area, so the diagnostic area. We have a lot of expertise around how to develop and promote new methods for supporting caregivers and persons with dementia. Alzheimer's trial brings at-risk patients hope for the future, but new doubts in the present We've got outstanding Indigenous cognitive health researchers that are developing new culturally safe and appropriate diagnostic and caregiving methods. And we do have some very good work going on around pathogenesis, looking at changes in the brain during aging and how that may lead to loss of cognition. That's important because you really need to understand where those earliest changes come from. Those are the targets where you need to develop drugs and therapies. This interview has been edited and condensed.
Globe and Mail
17 minutes ago
- Globe and Mail
Prediction: Nvidia Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Key Points Nvidia has the most powerful computer chips, and the major AI developers rely on them to drive their businesses. The total AI opportunity is expected to increase at a high rate over the next five years. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has been that rare stock that has catapulted investors to millionaire status on its own. But up more than 1,500% over the past five years, and with a $4 trillion market cap, can it really still offer growth for investors? It can. Here's why. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The age of AI All signs are that artificial intelligence (AI) will continue to drive innovation over the next few years as more businesses see how it can help them succeed and grow. As there's greater development in AI, it becomes cheaper and more abundant, and companies that aren't using it to become more efficient and user-friendly are losing out. Nvidia is the leader in the graphics processing units (GPU) that power these trends, with an overwhelming amount of market share. The AI market is growing at a fast pace, and the major players, like Amazon and Microsoft, need Nvidia's powerful chips to drive their efforts. Even companies like Amazon that are creating their own chips to offer more budget-conscious options still partner with Nvidia for their larger clients' needs. According to Statista, the AI market is expected to increase at a compound annual growth rate (CAGR) of 26.6% over the next five years. That's slower than Nvidia's current revenue growth. If you can imagine Nvidia keeping up such a CAGR for its own sales, keeping its price-to-sales ratio constant, that would lead to its stock price nearly tripling. Even if the price-to-sales ratio decreases, there could be some serious gains ahead for Nvidia investors over the next five years and beyond. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
CTV News
17 minutes ago
- CTV News
Company involved in Coldplay KissCam drama hires Gwyneth Paltrow as spokesperson
Gwyneth Paltrow arrives at the 11th Breakthrough Prize Ceremony on Saturday, April 5, 2025, in Los Angeles. (Photo by Jordan Strauss/Invision/AP, File) BOSTON — Astronomer — the company whose CEO resigned after being caught on a KissCam at a Coldplay rock concert embracing a woman who was not his wife — is trying to move on from the drama with someone who knows the band pretty well. Actress Gwyneth Paltrow, who was married to Coldplay's frontman Chris Martin for 13 years, announced Friday on X that she has been hired by Astronomer as a spokesperson. Astronomer, a tech company based in New York, found itself in an uncomfortable spotlight when two of its executives were caught on camera in an intimate embrace at a Coldplay concert — a moment that was then flashed on a giant screen in the stadium. CEO Andy Byron and human resource executive Kristin Cabot were caught by surprise when Martin asked the cameras to scan the crowd during a concert earlier this month. 'Either they're having an affair or they're just very shy,' Martin joked when the couple appeared on screen and quickly tried to hide their faces. In a short video, the 'Shakespeare in Love' and 'Ironman' star said she had been hired as a 'very temporary' spokesperson for Astronomer. 'Astronomer has gotten a lot of questions over the last few days and they wanted me to answer the most common ones,' Paltrow said, smiling and deftly avoiding mention of the KissCam fuss. 'We've been thrilled that so many people have a newfound interest in data workflow automation,' she said. 'We will now be returning to what we do best — delivering game-changing results for our customers.' When footage from the KissCam first spread online, it wasn't immediately clear who the couple were. Soon after the company identified the pair, and Byron resigned followed by Cabot. The video clip resulted in a steady stream of memes, parody videos and screenshots of the pair's shocked faces filling social media feeds. Online streams of Coldplay's songs jumped 20 per cent in the days after the video went viral, according to Luminate, an industry data and analytics company.
